MA29266B1 - Traitement de tumeurs metastatiques - Google Patents

Traitement de tumeurs metastatiques

Info

Publication number
MA29266B1
MA29266B1 MA30162A MA30162A MA29266B1 MA 29266 B1 MA29266 B1 MA 29266B1 MA 30162 A MA30162 A MA 30162A MA 30162 A MA30162 A MA 30162A MA 29266 B1 MA29266 B1 MA 29266B1
Authority
MA
Morocco
Prior art keywords
treatment
compound
metastatic tumors
tautomer
pharmaceutically acceptable
Prior art date
Application number
MA30162A
Other languages
English (en)
Inventor
De Menezes Daniel Lopes
Carla Heise
Xiaohua Xin
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36741085&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA29266(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Publication of MA29266B1 publication Critical patent/MA29266B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'INVENTION CONCERNE LES PROCÉDÉS DE TRAITEMENT D'UN CANCER MÉTASTATIQUE TEL QUE DES TUMEURS MÉTASTATIQUES QUI CONSISTENT À ADMINISTRER UN COMPOSÉ DE STRUCTURE (I), UN TAUTOMÈRE CE COMPOSÉ, UN SEL ACCEPTABLE SUR LE PLAN PHARMACEUTIQUE DE CE COMPOSÉ, UN SEL ACCEPTABLE SUR LE PLAN PHARMACEUTIQUE OU LE TAUTOMÈRE, OU UN MÉLANGE DE CEUX-CI À UN PATIENT. LE COMPOSÉ, LE TAUTOMÈRE, LE SEL DE COMPOSÉ, LE SEL DE TAUTOMÈRE OU UN MÉLANGE DE CEUX-CI PEUVENT ÊTRE UTILISÉS AFIN DE PRÉPARER DES MÉDICAMENTS DESTINÉS À TRAITER UN CANCER MÉTASTATIQUE. LA VARIABLE A POSSÈDE DES VALEURS DÉFINIES DANS CETTE INVENTION.
MA30162A 2005-01-27 2007-08-23 Traitement de tumeurs metastatiques MA29266B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64756805P 2005-01-27 2005-01-27
US66924505P 2005-04-06 2005-04-06
US72205305P 2005-09-29 2005-09-29

Publications (1)

Publication Number Publication Date
MA29266B1 true MA29266B1 (fr) 2008-02-01

Family

ID=36741085

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30162A MA29266B1 (fr) 2005-01-27 2007-08-23 Traitement de tumeurs metastatiques

Country Status (22)

Country Link
US (2) US20060183750A1 (fr)
EP (2) EP2301546B1 (fr)
JP (2) JP5371246B2 (fr)
KR (1) KR101387985B1 (fr)
CN (1) CN103893181A (fr)
AT (1) ATE526025T1 (fr)
AU (1) AU2006208012B2 (fr)
BR (1) BRPI0607285A2 (fr)
CA (1) CA2596084A1 (fr)
CY (1) CY1112570T1 (fr)
DK (1) DK1845990T3 (fr)
ES (2) ES2374570T3 (fr)
IL (1) IL184866A0 (fr)
MA (1) MA29266B1 (fr)
MX (1) MX2007009099A (fr)
NO (1) NO20074360L (fr)
PL (2) PL1845990T3 (fr)
PT (2) PT2301546E (fr)
SG (1) SG173317A1 (fr)
SI (1) SI2301546T1 (fr)
TN (1) TNSN07294A1 (fr)
WO (1) WO2006081445A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE448226T1 (de) 2000-09-01 2009-11-15 Novartis Vaccines & Diagnostic Aza heterocyclische derivate und ihre therapeutische verwendung
DE60115069T2 (de) 2000-09-11 2006-08-03 Chiron Corp., Emeryville Chinolinonderivate als tyrosin-kinase inhibitoren
EP1539754A4 (fr) 2002-08-23 2009-02-25 Novartis Vaccines & Diagnostic Quinolinones de benzimidazole et leurs utilisations
EP1885187B1 (fr) * 2005-05-13 2013-09-25 Novartis AG Procedes pour traiter un cancer pharmacoresistant
BRPI0611375A2 (pt) * 2005-05-23 2010-08-31 Novartis Ag formas cristalinas e outras de sais de ácido láctico de 4-amino-5-flúor-3-[6-(4-metilpiperazin-1-il)-1h-benzimid azol-2-il]-1h-quinolin-2-ona
PE20091628A1 (es) * 2008-03-19 2009-11-19 Novartis Ag Formas cristalinas y dos formas solvatadas de sales de acido lactico de 4-amino-5-fluoro-3-[5-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]quinolin-2(1h)-ona
EP2432451A2 (fr) * 2009-05-20 2012-03-28 Children's Medical Center Corporation Compositions pour le traitement du cancer metastatique et leurs procedes d'utilisation
BR112012026289A2 (pt) * 2010-04-16 2016-07-12 Novartis Ag composto orgânico para uso no tratamento de câncer do fígado
MX2013013437A (es) * 2011-05-19 2013-12-06 Novartis Ag 4-amino-5-fluoro-3- [6- (4-metil-piperazin-1-il) -1h-bencimidazol-2-il] -1h-quinolin-2-ona parea usarse en el tratamiento de un carcinoma adenoide quistico.
EP2809312A1 (fr) * 2012-01-31 2014-12-10 Novartis AG Combinaison d'un inhibiteur de rtk avec un anti- strogène et son utilisation pour traiter le cancer
KR102494647B1 (ko) * 2016-07-14 2023-01-31 브리스톨-마이어스 스큅 컴퍼니 비시클릭 헤테로아릴 치환된 화합물

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3663606A (en) * 1966-06-21 1972-05-16 Mitsui Toatsu Chemicals Organic imino-compounds
DE2363459A1 (de) 1973-12-20 1975-06-26 Basf Ag Neue fluoreszierende chinolinverbindungen
US4659657A (en) * 1982-12-24 1987-04-21 Bayer Aktiengesellschaft Chromogenic and fluorogenic esters for photometric or fluorimetric determination of phosphatases or sulphatases
US5073492A (en) * 1987-01-09 1991-12-17 The Johns Hopkins University Synergistic composition for endothelial cell growth
JPH0699497B2 (ja) 1987-04-16 1994-12-07 富士写真フイルム株式会社 光重合性組成物
DE3932953A1 (de) * 1989-10-03 1991-04-11 Boehringer Mannheim Gmbh Neue 2-bicyclo-benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
GB9108547D0 (en) 1991-04-22 1991-06-05 Fujisawa Pharmaceutical Co Quinoline derivatives
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
USRE37650E1 (en) * 1991-05-10 2002-04-09 Aventis Pharmacetical Products, Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5856115A (en) * 1991-05-24 1999-01-05 Fred Hutchinson Cancer Research Center Assay for identification therapeutic agents
PT627940E (pt) * 1992-03-05 2003-07-31 Univ Texas Utilizacao de imunoconjugados para o diagnostico e/ou terapia de tumores vascularizados
JP3142378B2 (ja) 1992-06-22 2001-03-07 ティーディーケイ株式会社 有機ｅｌ素子
US5792771A (en) * 1992-11-13 1998-08-11 Sugen, Inc. Quinazoline compounds and compositions thereof for the treatment of disease
US5763441A (en) * 1992-11-13 1998-06-09 Sugen, Inc. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5981569A (en) * 1992-11-13 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease
JPH0743896A (ja) 1993-07-28 1995-02-14 Toyobo Co Ltd 光重合性組成物
JPH0829973A (ja) 1994-07-11 1996-02-02 Toyobo Co Ltd 光重合性組成物
JP3441246B2 (ja) * 1995-06-07 2003-08-25 富士写真フイルム株式会社 光重合性組成物
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
DE19610723A1 (de) 1996-03-19 1997-09-25 Bayer Ag Elektrolumineszierende Anordnungen unter Verwendung von Blendsystemen
US5942385A (en) * 1996-03-21 1999-08-24 Sugen, Inc. Method for molecular diagnosis of tumor angiogenesis and metastasis
JP4373497B2 (ja) * 1996-06-19 2009-11-25 ローン−プーラン・ロレ・リミテツド 置換されたアザビシクロ化合物、ならびにｔｎｆおよびサイクリックａｍｐホスホジエステラーゼ産生の阻害剤としてのそれらの使用
WO1997048694A1 (fr) 1996-06-20 1997-12-24 Board Of Regents, The University Of Texas System Composes et procedes d'obtention de preparations pharmacologiquement actives et leurs utilisations
US6111110A (en) * 1996-10-30 2000-08-29 Eli Lilly And Company Synthesis of benzo[f]quinolinones
CA2387351C (fr) * 1999-10-19 2009-09-08 Merck & Co., Inc. Derives d'indole servant d'inhibiteurs de la tyrosine kinase
AU778042B2 (en) 1999-10-19 2004-11-11 Merck & Co., Inc. Tyrosine kinase inhibitors
EP1259236A4 (fr) 2000-02-25 2004-11-03 Merck & Co Inc Inhibiteurs de tyrosine-kinase
US6313138B1 (en) * 2000-02-25 2001-11-06 Merck & Co., Inc. Tyrosine kinase inhibitors
US6420382B2 (en) 2000-02-25 2002-07-16 Merck & Co., Inc. Tyrosine kinase inhibitors
ATE448226T1 (de) * 2000-09-01 2009-11-15 Novartis Vaccines & Diagnostic Aza heterocyclische derivate und ihre therapeutische verwendung
WO2002020500A2 (fr) * 2000-09-01 2002-03-14 Icos Corporation Substances potentialisant un traitement anticancereux et methodes a cet effet
DE60115069T2 (de) * 2000-09-11 2006-08-03 Chiron Corp., Emeryville Chinolinonderivate als tyrosin-kinase inhibitoren
US20030028018A1 (en) * 2000-09-11 2003-02-06 Chiron Coporation Quinolinone derivatives
US7064215B2 (en) * 2001-07-03 2006-06-20 Chiron Corporation Indazole benzimidazole compounds
EP1539754A4 (fr) * 2002-08-23 2009-02-25 Novartis Vaccines & Diagnostic Quinolinones de benzimidazole et leurs utilisations
US7825132B2 (en) * 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
SG148864A1 (en) * 2002-11-13 2009-01-29 Chiron Corp Methods of treating cancer and related methods
US6774327B1 (en) * 2003-09-24 2004-08-10 Agilent Technologies, Inc. Hermetic seals for electronic components
US20050209247A1 (en) * 2003-11-07 2005-09-22 Chiron Corporation Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties
EP1718306A2 (fr) * 2004-02-20 2006-11-08 Chiron Corporation Modulation de processus inflammatoires et metastatiques
BRPI0613200A2 (pt) * 2005-05-18 2012-01-03 M & G Polimeri Italia Spa composiÇço de poliÉster
KR102639757B1 (ko) 2017-01-09 2024-02-23 엘지이노텍 주식회사 카메라 모듈 및 이를 포함하는 광학기기

Also Published As

Publication number Publication date
WO2006081445A2 (fr) 2006-08-03
US20060183750A1 (en) 2006-08-17
WO2006081445A3 (fr) 2007-01-11
JP2013177464A (ja) 2013-09-09
PL2301546T3 (pl) 2015-03-31
CA2596084A1 (fr) 2006-08-03
JP2008528617A (ja) 2008-07-31
CN103893181A (zh) 2014-07-02
AU2006208012B2 (en) 2011-08-04
ES2374570T3 (es) 2012-02-17
PT1845990E (pt) 2011-12-23
IL184866A0 (en) 2007-12-03
US20100173873A1 (en) 2010-07-08
CY1112570T1 (el) 2016-02-10
DK1845990T3 (da) 2012-01-02
EP2301546A1 (fr) 2011-03-30
KR20070118596A (ko) 2007-12-17
MX2007009099A (es) 2007-09-13
EP1845990A4 (fr) 2008-04-30
PL1845990T3 (pl) 2012-02-29
NO20074360L (no) 2007-10-25
BRPI0607285A2 (pt) 2009-08-25
HK1155664A1 (en) 2012-05-25
EP1845990A2 (fr) 2007-10-24
JP5371246B2 (ja) 2013-12-18
EP2301546B1 (fr) 2014-09-10
PT2301546E (pt) 2014-12-18
SG173317A1 (en) 2011-08-29
AU2006208012A1 (en) 2006-08-03
TNSN07294A1 (en) 2008-12-31
ATE526025T1 (de) 2011-10-15
ES2525670T3 (es) 2014-12-29
EP1845990B1 (fr) 2011-09-28
KR101387985B1 (ko) 2014-04-25
SI2301546T1 (sl) 2015-01-30

Similar Documents

Publication Publication Date Title
MA29266B1 (fr) Traitement de tumeurs metastatiques
NO20091661L (no) Anvendelse av pegylert IL-10 for a behandle kreft
NO2017019I2 (no) Enzalutamid eller et farmasøytisk akseptabelt salt derav
IL184951A0 (en) Meleimide derivatives, pharmaceutical compositions and methods for treatment of cancer
MX2007002398A (es) Nuevas composiciones farmaceuticas para el tratamiento de cancer.
EA200870415A1 (ru) Хиназолины для ингибирования pdk 1
EA201001143A1 (ru) Активаторы прокаспаз "исполнителей" 3, 6 и 7
EA200700225A1 (ru) Аналоги тетрапептида
EP1951729A4 (fr) Derives de pyrimidine a liaison oxygene
WO2006102504A3 (fr) Combinaisons destinees au traitement de cancer
MX2009009574A (es) Tratamiento de melanoma.
WO2006044826A3 (fr) Compositions et leur utilisation en tant qu'agents antitumoraux
CR8696A (es) Beta-carbolinas utiles para tratar enfermedades inflamatorias
WO2006044975A3 (fr) Compositions et leur utilisation comme agents antitumoraux
TW200740812A (en) 1,4-Dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them
WO2005085188A3 (fr) Composes et procedes pour la therapie antitumorale
WO2007076087A3 (fr) Quinazolones d'aryle substitue et leurs utilisations
EA200801425A1 (ru) Диазепиноны
ATE435647T1 (de) Rutheniumkomplexe zur krebsbehandlung
GB0305928D0 (en) Organic compounds